DDAH1 and prostate carcinoma: DDAH1 is frequently upregulated in prostate cancer, where it promotes tumor growth and angiogenesis, suggesting that anti-cancer drugs that induce ADMA or that inhibit DDAH1 could potentially be useful in treating tumors that are influenced by the pro-tumorigenic properties of NO (Reddy et al., 2018).